LBA
ELVN icon

Letko, Brosseau & Associates’s Enliven Therapeutics ELVN Stock Holding History

Letko, Brosseau & Associates’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487K Hold
9,600
– – 0.01% 83
2026
Q1 		$376K Buy
+9,600
New +$266K 0.01% 83

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Letko, Brosseau & Associates's ELVN Position: Q2 2026 in Review

Letko, Brosseau & Associates held its Enliven Therapeutics (ELVN) position steady in Q2 2026 at 9,600 shares worth $487K. The position accounts for 0.01% of the portfolio, ranked #83.

Letko, Brosseau & Associates first reported a position in ELVN in Q1 2026 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Letko, Brosseau & Associates held 9,600 shares of Enliven Therapeutics worth $487K as of Q2 2026.
  • Letko, Brosseau & Associates left its Enliven Therapeutics share count unchanged in Q2 2026.
  • Enliven Therapeutics made up 0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #83 holding.
  • Letko, Brosseau & Associates first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.